- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
Navigating TYK-2 Inhibitor Use for Psoriasis Maintenance and Long-Term Benefits
Author(s):
Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices. They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.
Panelists:
Linda Stein-Gold, MD
Henry Ford Health
Detroit, Michigan
Mona Shahriari, MD
Yale University
New Haven, Connecticut
Micheal Cameron, MD, FAAD
Cameron Dermatology
New York, New York
Leon Kircik, MD
DermResearch, PLLC
Louisville, Kentucky
George Han, MD
Hofstra University
Long Island, New York
Program Description:
Experts in the management of skin conditions discuss the latest developments in plaque psoriasis management, covering emerging oral therapies, novel topical treatments, and advancements in biologic therapy. The discussion provides practical insights for healthcare professionals to integrate these innovations into daily clinical practice for optimal patient outcomes. Additionally, the panel addresses the strategic placement of emerging therapies within current treatment guidelines, ensuring participants stay informed about the evolving landscape of psoriasis care.
Segment Description:
Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices. They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.
